home / stock / nbrv / nbrv news


NBRV News and Press, Nabriva Therapeutics plc From 05/01/19

Stock Information

Company Name: Nabriva Therapeutics plc
Stock Symbol: NBRV
Market: NASDAQ

Menu

NBRV NBRV Quote NBRV Short NBRV News NBRV Articles NBRV Message Board
Get NBRV Alerts

News, Short Squeeze, Breakout and More Instantly...

NBRV - FTR, NUS, PBI and ENPH among midday movers

Gainers:  ARCA biopharma (NASDAQ: ABIO ) +37% . MFC Bancorp (NYSE: MFCB ) +32% . Enphase Energy (NASDAQ: ENPH ) +29% . Precipio (NASDAQ: PRPO ) +25% . Nu Skin Enterprises (NYSE: NUS ) +25% . Nanometrics Incorporated (NASDAQ: NANO ) +22% . Qumu Corporation (NASDAQ: QUMU ) +22% ....

NBRV - SSNC and PBI among premarket losers

Heron Therapeutics (NASDAQ: HRTX )  -24%  after FDA rejects application for pain med HTX-011. More news on: Heron Therapeutics, Inc., Nabriva Therapeutics plc, CM Seven Star Acquisition Corporation, Stocks on the move, Read more ...

NBRV - FDA rejects Nabriva's Contepo application; shares down 28% premarket

Nabriva Therapeutics (NASDAQ: NBRV ) has received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval for CONTEPO (fosfomycin) for the treatment of complicated urinary tract infections, including acute pyelonephritis. More news on: Nabriva T...

NBRV - Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for Intravenous CONTEPO(TM) (fosfomycin) for injection

Issues related to facility inspections and manufacturing deficiencies at one contract manufacturer Conference call and webcast tomorrow at 8:00 a.m. EDT DUBLIN, Ireland, April 30, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical ...

NBRV - Nabriva -9.4% on FDA review date for Contepo

Nabriva Therapeutics (NASDAQ: NBRV ) is off 9.4% after hours on the arrival of its priority review for Contepo (fosfomycin). More news on: Nabriva Therapeutics plc, Healthcare stocks news, Stocks on the move Read more ...

NBRV - Eyes On Apple, Uber, F8 And Avengers (Stocks To Watch Podcast)

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

NBRV - Stocks To Watch: Eyes On Apple, Uber, F8 And Avengers

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...

NBRV - Key events next week - healthcare (Part 1)

Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...

NBRV - Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinica...

NBRV - Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO(TM) (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs)

DUBLIN, Ireland, April 11, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the 29 th European Congress of C...

Previous 10 Next 10